Key result
Reperfusion therapies for acute PE were associated with a greater absolute reduction in vascular obstructive index (45% vs 26%; P<0.001) and lower 12-month mortality (2% vs 7%; P=0.038).
Why the study?
Although reperfusion strategies have improved short-term outcomes in pulmonary embolism, up to 50% of patients report persistent dyspnea after acute PE.
Do reperfusion therapies improve clot resolution and long-term outcomes in patients with acute pulmonary embolism?
Population
382 acute PE patients with repeat imaging at 3 to 12 months
Comparison
Reperfusion therapies followed by anticoagulation vs anticoagulation alone
Design
Retrospective registry study
Follow-up
12 months
Authors
Loading...
May support reperfusion in acute PE; leaves open whether RCTs confirm mortality benefit.
Cohort (n=382)
Do reperfusion therapies improve clot resolution and long-term outcomes in patients with acute pulmonary embolism?
Absolute Event Rate: 45% vs 26%
p-value: p=<.001
In patients with acute pulmonary embolism, reperfusion therapies are associated with greater clot resolution, improved right ventricular function, and lower 12-month mortality and readmission rates compared to non-reperfusion strategies.
Lio et al. (2024) conducted a cohort in pulmonary embolism (n=382). Reperfusion therapies vs. Anticoagulation alone was evaluated on Incidence of residual pulmonary vascular obstruction (measured as absolute reduction in vascular obstructive index) (95% CI 14.0-25.6, p=<.001). Reperfusion therapies for acute PE were associated with a greater absolute reduction in vascular obstructive index (45% vs 26%; P<0.001) and lower 12-month mortality (2% vs 7%; P=0.038).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: